Search research articles
Contact Us
Filters
Showing results (301-310 of 397) with videos related to
Page
of 40
Sort By:
Oncotarget
|
November 7, 2014
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab
Gerald S Falchook, Jennifer J Wheler, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2021
Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors
Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, et al.
Cancer
|
October 21, 2023
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies
Anne Knisely, Jibran Ahmed, Bettzy Stephen, et al.
Nature
|
September 16, 2014
Asian monsoons in a late Eocene greenhouse world
A Licht, M van Cappelle, H A Abels, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 16, 2014
Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic
Chad Tang, Kenneth Hess, Denis Leonardo F Jardim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 3, 2024
Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors
Giuseppe Curigliano, Hans Curigliano, Nicolas Mach, et al.
Oncology
|
November 2, 2016
Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit
Holly Kinahan, Abhishek Maiti, Kenneth Hess, et al.
Investigational New Drugs
|
October 27, 2021
Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
Kyaw Zin Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Journal for Immunotherapy of Cancer
|
August 21, 2023
T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy
Bettzy Stephen, Joud Hajjar, Shrutii Sarda, et al.
Investigational New Drugs
|
September 25, 2021
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study
Kyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Page
of 40
Search research articles
Search
Showing results (301-310 of 397) with videos related to
Sort By:
Page
of 40
Oncotarget
|
November 7, 2014
Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab
Gerald S Falchook, Jennifer J Wheler, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 22, 2021
Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors
Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, et al.
Cancer
|
October 21, 2023
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies
Anne Knisely, Jibran Ahmed, Bettzy Stephen, et al.
Nature
|
September 16, 2014
Asian monsoons in a late Eocene greenhouse world
A Licht, M van Cappelle, H A Abels, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 16, 2014
Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic
Chad Tang, Kenneth Hess, Denis Leonardo F Jardim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 3, 2024
Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors
Giuseppe Curigliano, Hans Curigliano, Nicolas Mach, et al.
Oncology
|
November 2, 2016
Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit
Holly Kinahan, Abhishek Maiti, Kenneth Hess, et al.
Investigational New Drugs
|
October 27, 2021
Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
Kyaw Zin Thein, Sarina A Piha-Paul, Apostolia Tsimberidou, et al.
Journal for Immunotherapy of Cancer
|
August 21, 2023
T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy
Bettzy Stephen, Joud Hajjar, Shrutii Sarda, et al.
Investigational New Drugs
|
September 25, 2021
Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study
Kyaw Z Thein, Daniel D Karp, Apostolia Tsimberidou, et al.
Page
of 40